Kymera
degrader first in class opportunity to address driven pathology across diverse indications first degrader against an undrugged target in the clinic profound single agent activity in liquid tumor and promising activity with anti in liquid and solid tumors clinical development strategy includes direct registrational path in pathway activated heme malignancies opportunity for expansion into solid tumors in combination with immune inhibitors | Kymera
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
66 of 105
Related slides by other companies
Nuvalent
Investor Presentation
October 2023
for positive advanced and other solid tumors resistance mutations | Nuvalent
Mink Therapeutics
Investor Day
November 2022
mitochondrial fitness essential for tumor activity | Mink Therapeutics
Recursion Pharmaceuticals
Investor Day
January 2023
for the treatment of solid tumors with mutant cancers | Recursion Pharmaceuticals
Recursion Pharmaceuticals
Investor Day
January 2023
clinical sustained signaling is a frequent driver event found across a wide variety of solid tumors of destruction complex due to inactivating mutations in leads to sustained signaling promoting cancer progression and survival mutant solid tumors are considered clinically aggressive and resistant to standard treatments disease overview cancers | Recursion Pharmaceuticals
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io